Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityNo recent work listed

Yiyin Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4887-2401; OpenAlex author ID A5036813587. Sources: OpenAlex.

Their work

Papers
20 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
39
Papers, trials and grants by year

2018: 4 papers · 2019: 4 papers · 2020: 6 papers · 2021: 1 paper · 2022: 1 paper · 2023: 4 papers

Papers 20

  1. Identification of exosomal miR-484 role in reprogramming mitochondrial metabolism in pancreatic cancer through Wnt/MAPK axis control. Co-author DOI 10.1016/j.phrs.2023.106980↗
  2. Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response. Co-author DOI 10.1016/j.xcrm.2023.101234↗
  3. CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-κB/p65 nuclear translocation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2022-329349↗
  4. Microbiota Regulates Pancreatic Cancer Carcinogenesis through Altered Immune Response. Co-author DOI 10.3390/microorganisms11051240↗
  5. Platelet-Vesicles-Encapsulated RSL-3 Enable Anti-Angiogenesis and Induce Ferroptosis to Inhibit Pancreatic Cancer Progress. Co-author DOI 10.3389/fendo.2022.865655↗
  6. Comment on "Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma". Co-author DOI 10.1097/sla.0000000000003989↗
  7. TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status. Co-author DOI 10.1080/15548627.2019.1628540↗
  8. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. Co-author DOI 10.1186/s12943-020-01167-9↗
  9. Comments: The Prognostic Index Independently Predicts Survival in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Resection. First author DOI 10.1245/s10434-020-08369-x↗
  10. The value of a metabolic reprogramming-related gene signature for pancreatic adenocarcinoma prognosis prediction. Co-author DOI 10.18632/aging.104134↗
  11. A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance. Co-author DOI 10.7150/thno.40566↗
  12. The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma. First author DOI 10.7717/peerj.9602↗
  13. Prognostic and diagnostic significance of galectins in pancreatic cancer: a systematic review and meta-analysis. First author DOI 10.1186/s12935-019-1025-5↗
  14. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s40425-019-0703-0↗
  15. Role of Damage DNA-Binding Protein 1 in Pancreatic Cancer Progression and Chemoresistance. Co-author DOI 10.3390/cancers11121998↗
  16. Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.7150/jca.29898↗
  17. Anergic natural killer cells educated by tumor cells are associated with a poor prognosis in patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00262-018-2235-8↗
  18. MUC16 C terminal-induced secretion of tumor-derived IL-6 contributes to tumor-associated Treg enrichment in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2018.01.017↗
  19. GPx1 is involved in the induction of protective autophagy in pancreatic cancer cells in response to glucose deprivation. Co-author DOI 10.1038/s41419-018-1244-z↗
  20. Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions. Co-author DOI 10.1186/s13045-017-0551-7↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 16 shared papers, 2018–2023 · strength 1.73
  2. Si Shi · 12 shared papers, 2018–2023 · strength 1.40
  3. Qingcai Meng · 11 shared papers, 2018–2023 · strength 1.21
  4. Jie Hua · 11 shared papers, 2018–2023 · strength 1.21
  5. Chen Liang · 10 shared papers, 2018–2023 · strength 1.10
  6. Jin Xu · 10 shared papers, 2018–2023 · strength 1.05
  7. Yuelong Liang · 3 shared papers, 2022–2023 · strength 0.52
  8. Rong Tang · 3 shared papers, 2020–2023 · strength 0.41
  9. Miaoyan Wei · 4 shared papers, 2019–2020 · strength 0.41
  10. Jiang Liu · 4 shared papers, 2019–2020 · strength 0.40
  11. Bo Zhang · 3 shared papers, 2020–2023 · strength 0.36
  12. Tianyu Lin · 2 shared papers, 2022–2023 · strength 0.33
  13. Wei Wang · 2 shared papers, 2023 · strength 0.30
  14. Qiqing Sun · 2 shared papers, 2019–2020 · strength 0.30
  15. Zhen Tan · 2 shared papers, 2020–2023 · strength 0.26
  16. Chao Yang · 3 shared papers, 2018 · strength 0.22
  17. Kun Fan · 3 shared papers, 2018 · strength 0.22
  18. Zhiyao Fan · 3 shared papers, 2018 · strength 0.22
  19. Chen Liu · 3 shared papers, 2018 · strength 0.22
  20. Guopei Luo · 3 shared papers, 2018 · strength 0.22
  21. Kaizhou Jin · 3 shared papers, 2018 · strength 0.22
  22. Yi-Han Chai · 1 shared paper, 2023 · strength 0.19
  23. Xiaowu Xu · 1 shared paper, 2020 · strength 0.19
  24. Guoping Ding · 1 shared paper, 2023 · strength 0.18
  25. Xiaofan Pu · 1 shared paper, 2023 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.